Caris Life Sciences Sustainability Profile
Caris Life Sciences, a leading innovator in the field of precision medicine, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2008, the company has established itself as a key player in the biotechnology industry, focusing on molecular profiling and advanced diagnostics to enhance cancer treatment. Caris Life Sciences offers a range of unique services, including comprehensive genomic profiling and biomarker testing, which empower healthcare providers to tailor therapies to individual patients. The company’s commitment to advancing personalised medicine has garnered recognition, positioning it as a trusted partner in oncology. With a robust portfolio of cutting-edge technologies, Caris Life Sciences continues to drive significant advancements in patient care and treatment outcomes.
DitchCarbon Score
How does Caris Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Caris Life Sciences's score of 28 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Caris Life Sciences's reported carbon emissions
In 2023, Caris Life Sciences reported total emissions of approximately 6.0 billion kg CO2e, comprising about 1.5 billion kg CO2e from Scope 1 and 2 emissions and approximately 4.6 billion kg CO2e from Scope 3 emissions. This reflects a decrease from 2022, where total emissions were about 8.4 billion kg CO2e, with Scope 1 and 2 emissions at approximately 1.8 billion kg CO2e and Scope 3 emissions at about 6.7 billion kg CO2e. Despite these figures, Caris Life Sciences has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company does not appear to inherit emissions data from a parent organisation, maintaining its own reporting structure. Overall, while Caris Life Sciences has made strides in reducing its emissions year-on-year, the lack of formal climate commitments or reduction targets suggests an opportunity for further engagement in climate action and sustainability initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | 6,680,000,000 | 0,000,000,000 |
How Carbon Intensive is Caris Life Sciences's Industry?
How Carbon Intensive is Caris Life Sciences's Location?
Caris Life Sciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Caris Life Sciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
